GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (FRA:PH7) » Definitions » PS Ratio

PYC Therapeutics (FRA:PH7) PS Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2010. Start your Free Trial

What is PYC Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PYC Therapeutics's share price is €0.089. PYC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Hence, PYC Therapeutics's PS Ratio for today is .

The historical rank and industry rank for PYC Therapeutics's PS Ratio or its related term are showing as below:

During the past 13 years, PYC Therapeutics's highest PS Ratio was 182.82. The lowest was 3.22. And the median was 36.70.

FRA:PH7's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.8
* Ranked among companies with meaningful PS Ratio only.

PYC Therapeutics's Revenue per Sharefor the six months ended in Dec. 2023 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

During the past 13 years, PYC Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -20.60% per year. The lowest was -45.00% per year. And the median was -30.70% per year.

Back to Basics: PS Ratio


PYC Therapeutics PS Ratio Historical Data

The historical data trend for PYC Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PYC Therapeutics PS Ratio Chart

PYC Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PYC Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PYC Therapeutics's PS Ratio

For the Biotechnology subindustry, PYC Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's PS Ratio falls into.



PYC Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

PYC Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.089/0
=

PYC Therapeutics's Share Price of today is €0.089.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


PYC Therapeutics  (FRA:PH7) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


PYC Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of PYC Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PYC Therapeutics (FRA:PH7) Business Description

Traded in Other Exchanges
Address
6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics (FRA:PH7) Headlines

No Headlines